Bioanalytical method validation for the simultaneous determination of ceftazidime and avibactam in rat plasma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bioanalytical method validation for the simultaneous determination of ceftazidime and avibactam in rat plasma
Authors
Keywords
-
Journal
Bioanalysis
Volume 8, Issue 2, Pages 111-122
Publisher
Future Science, LTD
Online
2015-12-10
DOI
10.4155/bio.15.233
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Avibactam Alone and in Combination with Ceftazidime in Healthy Male Volunteers: Results of Two Randomized, Placebo-Controlled Studies
- (2015) Henri Merdjan et al. CLINICAL DRUG INVESTIGATION
- Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime–avibactam in healthy Japanese volunteers
- (2015) Nobumitsu Tominaga et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- Novel Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Detection of Anti-HIV Drugs Lopinavir, Ritonavir, and Tenofovir in Plasma
- (2014) J. Koehn et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Combination therapy in severe Acinetobacter baumannii infections: an update on the evidence to date
- (2014) Emanuele Durante-Mangoni et al. Future Microbiology
- Bioanalytical chromatographic method validation according to current regulations, with a special focus on the non-well defined parameters limit of quantification, robustness and matrix effect
- (2014) Oskar González et al. JOURNAL OF CHROMATOGRAPHY A
- Development and validation of bioanalytical method for simultaneous estimation of ramipril and hydrochlorothiazide in human plasma using liquid chromatography-tandem mass spectrometry
- (2014) Jatin R. Patel et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
- (2014) Mark S. Sulkowski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination Therapy Including Glucocorticoids: The New Gold Standard for Early Treatment in Rheumatoid Arthritis?
- (2013) John Richard Kirwan ANNALS OF INTERNAL MEDICINE
- Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value
- (2013) Robert K. Flamm et al. JOURNAL OF CHEMOTHERAPY
- Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam
- (2013) Shampa Das et al. JOURNAL OF CLINICAL PHARMACOLOGY
- ComparativeIn VitroandIn VivoEfficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa
- (2012) Jared L. Crandon et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of Ceftaroline-Avibactam Tested against Gram-Negative Organism Populations, including Strains Expressing One or More β-Lactamases and Methicillin-Resistant Staphylococcus aureus Carrying Various Staphylococcal Cassette ChromosomemecTypes
- (2012) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroAntibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical Isolates
- (2012) Premavathy Levasseur et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A review of topiramate and phentermine: a combined therapeutic approach for obesity
- (2012) Domenica M Rubino et al. Clinical Lipidology
- Carbapenemases in Klebsiella pneumoniae and Other Enterobacteriaceae: an Evolving Crisis of Global Dimensions
- (2012) L. S. Tzouvelekis et al. CLINICAL MICROBIOLOGY REVIEWS
- Optimization of current and future therapy for autoimmune diseases
- (2012) Lawrence Steinman et al. NATURE MEDICINE
- Current Epidemiology and Growing Resistance of Gram-Negative Pathogens
- (2012) David M. Livermore KOREAN JOURNAL OF INTERNAL MEDICINE
- Future of fixed-dose longacting β2-agonist and antimuscarinic combination therapy in COPD
- (2012) Donald P Tashkin Lancet Respiratory Medicine
- Ready for a world without antibiotics? The Pensières Antibiotic Resistance Call to Action
- (2012) Jean Carlet et al. Antimicrobial Resistance and Infection Control
- Activity of NXL104 in Combination with β-Lactams against Genetically Characterized Escherichia coli and Klebsiella pneumoniae Isolates Producing Class A Extended-Spectrum β-Lactamases and Class C β-Lactamases
- (2011) P. R. S. Lagacé-Wiens et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae
- (2011) Z. Aktaş et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Liquid chromatography–tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma
- (2011) Rolf W. Sparidans et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma
- (2011) Constantine S. Mitsiades et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination therapy: the next opportunity and challenge of medicine
- (2011) Paolo A Ascierto et al. Journal of Translational Medicine
- Current Concepts in Antimicrobial Therapy Against Resistant Gram-Negative Organisms: Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae, Carbapenem-Resistant Enterobacteriaceae, and Multidrug-Resistant Pseudomonas aeruginosa
- (2011) Souha S. Kanj et al. MAYO CLINIC PROCEEDINGS
- Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-ProducingEnterobacteriaceae
- (2010) David M. Livermore et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Infections with Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae
- (2010) Johann D.D. Pitout DRUGS
- Activity of chequerboard combinations of ceftaroline and NXL104 versus -lactamase-producing Enterobacteriaceae
- (2010) S. Mushtaq et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials
- (2009) David S. Wald et al. AMERICAN JOURNAL OF MEDICINE
- In vitro activity of the -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases
- (2009) T. Stachyra et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum -lactamases and carbapenemases
- (2008) D. M. Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More